A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04385303 |
|
Recruitment Status :
Completed
First Posted : May 12, 2020
Last Update Posted : March 3, 2022
|
Sponsor:
Biosplice Therapeutics, Inc.
Information provided by (Responsible Party):
Biosplice Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. This study will utilize patient reported outcomes (PROs) to evaluate the safety and efficacy of lorecivivint.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Knee Osteoarthritis | Drug: Lorecivivint Drug: Placebo | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 498 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects |
| Actual Study Start Date : | May 26, 2020 |
| Actual Primary Completion Date : | September 8, 2021 |
| Actual Study Completion Date : | September 8, 2021 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Osteoarthritis
MedlinePlus related topics:
Osteoarthritis
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Lorecivivint
Healthcare professional-administered intra-articular injection; performed on Day 1.
|
Drug: Lorecivivint
One intra-articular injection of 0.07 mg lorecivivint in 2 m vehicle
Other Name: SM04690 |
|
Placebo Comparator: Vehicle
Healthcare professional-administered intra-articular injection; performed on Day 1.
|
Drug: Placebo
One intra-articular injection of 0 mg lorecivivint in 2 m vehicle
Other Name: Vehicle |
Primary Outcome Measures :
- Change from baseline OA pain in the target knee as assessed by the weekly average of daily pain numeric rating scale (NRS) at Week 12 [ Time Frame: Baseline and Week 12 ]Evaluate change from baseline OA pain in the target knee as assessed by the weekly average of daily pain NRS at Week 12. The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain.
Secondary Outcome Measures :
- Change from baseline OA pain in the target knee as assessed by the weekly average of daily pain numeric rating scale (NRS) at Week 24 [ Time Frame: Baseline and Week 24 ]Evaluate change from baseline OA pain in the target knee as assessed by the weekly average of daily pain NRS at Week 24. The pain NRS is an 11-point scale [0-10] for subject self-reporting of average knee pain in the last 24 hours; 0 indicates no pain, and 10 represents the worst possible pain.
- Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) physical function subscore (WOMAC Function) at Weeks 12 and 24 [ Time Frame: Baseline, Weeks 12 and 24 ]Evaluate change from baseline OA function in the target knee as assessed by WOMAC Function subscore at Weeks 12 and 24. The WOMAC is a widely-used, proprietary outcome measurement tool used to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 4 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore ranges from 0 to 68.
- Change from baseline OA disease activity as assessed by Patient Global Assessment at Weeks 12 and 24 [ Time Frame: Baseline, Weeks 12 and 24 ]Evaluate change from baseline OA disease activity as assessed by Patient Global Assessment at Weeks 12 and 24. The Patient Global Assessment is an 11-point [0-10] Numeric Rating Scale [NRS] on which the subjects will rate how they feel their target knee OA is doing, considering all the ways in which their target knee OA may affect them. The NRS is anchored by descriptors at each end ("Very Good" on the left and "Very Bad" on the right).
- Change from baseline in usage of nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for target knee OA pain at Week 24 [ Time Frame: Baseline, Week 24 ]Evaluate change from baseline in usage of NSAIDs and acetaminophen for target knee OA pain at Week 24.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 40 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Key Inclusion Criteria:
- Males and females between 40 and 80 years of age, inclusive, in general good health apart from their knee OA
- Ambulatory (single assistive devices such as canes allowed if needed less than 50% of the time, subjects requiring a walker are excluded)
- Diagnosis of femorotibial OA in the target knee by standard American College of Rheumatology (ACR) criteria at the Screening Visit (clinical AND radiographic criteria); OA of the knee is not to be secondary to any rheumatologic conditions (e.g., rheumatoid arthritis)
- Radiographic disease Stage 2 or 3 in target knee within 24 weeks of the Screening Visit according to the Kellgren-Lawrence (KL) grading of knee OA as assessed by independent central readers
- Qualifying mean score on the 24-h average pain score (0-10 numeric rating scale)
- Pain compatible with OA of the knee(s) for at least 26 weeks prior to the Screening Visit
- Primary source of pain throughout the body is due to OA in the target knee
- Body mass index (BMI) ≤ 35 kg/m2 at the Screening Visit
- Negative drug test for amphetamine, buprenorphine, cocaine, methadone, opiates, phencyclidine (PCP), propoxyphene, barbiturates, benzodiazepine, methaqualone, and tricyclic antidepressants, unless any of these drugs are allowed per protocol and prescribed by a physician to treat a specific condition
Key Exclusion Criteria:
- Pregnant women, breastfeeding women, and women who are not post-menopausal (defined as 12 months with no menses without an alternative medical cause) or permanently surgically sterile (includes hysterectomy, bilateral salpingectomy, and bilateral oophorectomy) who have a positive or indeterminate pregnancy test result at the Screening Visit or Day 1
- Significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the target knee (varus > 10°, valgus > 10°) by radiograph within 24 weeks of the Screening Visit as assessed by independent central readers
- Partial or complete joint replacement in either knee
- Currently requires use of a lower extremity prosthesis, and/or a structural knee brace (i.e., a knee brace that contains hardware)
- Any surgery (e.g., arthroscopy) in either knee within 26 weeks prior to Day 1
- Intra-articular (IA) injection into the target knee with a therapeutic aim including, but not limited to hyaluronic acid, platelet-rich plasma (PRP), and stem cell therapies within 26 weeks prior to Day 1; or IA glucocorticoids within 12 weeks prior to Day 1 allowed
- Previous treatment with lorecivivint (SM04690)
- Subjects who have previously failed screening on this protocol and fail to meet re-screening criteria
- Participation in a clinical research trial that included the receipt of an investigational product or any experimental therapeutic procedure within 26 weeks prior to the Screening Visit, or planned participation in any such trial
- Subjects requiring the use of opioids > 1x per week within 12 weeks prior to Day 1
- History of malignancy within the last 5 years; not including subjects with prior history of adequately treated in situ cervical cancer or basal or squamous cell skin cancer
- Clinically significant abnormal screening hematology values, blood chemistry values, or urinalysis values as determined by the Investigator
- Any known active infections, including urinary tract infection, upper respiratory tract infection, sinusitis, suspicion of IA infection, hepatitis B or hepatitis C infection, and/or infections that may compromise the immune system such as human immunodeficiency virus (HIV) at Day 1
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04385303
Locations
Show 76 study locations
Sponsors and Collaborators
Biosplice Therapeutics, Inc.
Investigators
| Study Director: | Yusuf Yazici, M.D. | Biosplice Therapeutics, Inc. |
| Responsible Party: | Biosplice Therapeutics, Inc. |
| ClinicalTrials.gov Identifier: | NCT04385303 |
| Other Study ID Numbers: |
SM04690-OA-10 |
| First Posted: | May 12, 2020 Key Record Dates |
| Last Update Posted: | March 3, 2022 |
| Last Verified: | March 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Biosplice Therapeutics, Inc.:
|
SM04690 Wnt pathway inhibitor osteoarthritis Samumed lorecivivint |
Additional relevant MeSH terms:
|
Osteoarthritis Osteoarthritis, Knee Arthritis Joint Diseases |
Musculoskeletal Diseases Rheumatic Diseases Lorecivivint Anti-Inflammatory Agents |